Cart
sales@molnova.com
CBP/EP300-IN-1
CAS No. 2443789-32-8
CBP/EP300-IN-1( —— )
Catalog No. M28557 CAS No. 2443789-32-8
CBP/EP300-IN-1 is a CBP/EP300 bromodomain inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 102 | In Stock |
|
| 2MG | 56 | In Stock |
|
| 5MG | 93 | In Stock |
|
| 10MG | 155 | In Stock |
|
| 25MG | 264 | In Stock |
|
| 50MG | 365 | In Stock |
|
| 100MG | 518 | In Stock |
|
| 200MG | 705 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCBP/EP300-IN-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionCBP/EP300-IN-1 is a CBP/EP300 bromodomain inhibitor.
-
DescriptionCBP/EP300-IN-1 is a CBP/EP300 bromodomain inhibitor.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayChromatin/Epigenetic
-
TargetEpigenetic Reader Domain
-
RecptorRARα|RARβ
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2443789-32-8
-
Formula Weight426.44
-
Molecular FormulaC23H23FN2O5
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 62.5 mg/mL (146.56 mM)
-
SMILESCC(N1C2=CC=C(OC)C=C2C(C(NC3=C(F)C=CC(C(OC(C)(C)C)=O)=C3)=O)=C1)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Jetten AM, et al. New benzoic acid derivatives with retinoid activity: lack of direct correlation between biological activity and binding to cellular retinoic acid binding protein. Cancer Res. 1987 Jul 1;47(13):3523-7.
molnova catalog
related products
-
Piflufolastat
Piflufolastat (DCFPYL) is a PET imaging agent for prostate cancer PSMA. It is a fluorinated prostate-specific membrane antigen (PSMA) preparation.
-
Dihydroactinidiolide
Dihydroactinidiolideis avolatileterpene. It has a sweet,tea-likeodorand is used as a fragrance.
-
PBRM1-BD2-IN-5
PBRM1-BD2-IN-5 is a potent inhibitor of the PBRM1 Bromodomain, with dissociation constant (Kd) values of 1.5 μM and 3.9 μM for PBRM1-BD2 and PBRM1-BD5 respectively, and an inhibitory concentration 50 (IC50) value of 0.26 μM for PBRM1-BD2.
